Nemera, a world-leading drug delivery device solutions provider, has introduced its multidose eye dropper Novelia. This has been approved by ANVISA , the Brazilian regulatory authority for the preservative-free formulations. These are Clilon contains Ketorolac which is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.
The over five decade old São Paulo based Aché is one of the largest domestic pharmaceutical company in Brazil.
The Ketorolac products will be the first of their kind commercialized in a preservative-free multi-dose format in the Brazilian market. These products will be available under prescription only. Aché is also launching, in parallel, Laxime (sodium hyaluronate) over the counter (OTC) solution for patients with dry eye syndrome using Novelia.
The Brazilian market presented a 4% growth with Dry Eye Disease experiencing double digit growth making it the no. 1 category in Brazil within the Ophthalmology Market “The entry of Aché in this segment represents an important reinforcement to the company's large portfolio. With the mission of enhancing people’s health and longevity, we understand that we also needed to work with ophthalmology to bring the quality and technology of Aché's products to this medical class.
“Our objective is not only to offer other options for the medical indication, but also to bring innovation to the Brazilian market in the coming years, and this partnership with Nemera will add great value to our products,” Marcelo Neri, executive director, Aché.
“With a growing number of patients suffering from chronic eye conditions, effective drug delivery and patient adherence are increasingly important. Combining the huge advantages of preservative-free formulations to avoid patient irritations with the ease of a multi-dose container system is a win-win and we are very proud to be partnering with Aché in this launch,” said Denise Johnston, vice president global sales, Nemera.
“We work to improve the lives of millions of patients across the world by designing, developing and manufacturing innovative drug delivery device solutions. Our vision as a team is to become the most patient-centric drug device combination solutions company in the industry. We partner closely with our customers to deliver innovative and high-quality devices, to ensure that patients will receive the best product and service possible,” he added.
Novelia is a multidose closing tip dispensing system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment. A non-return valve system ensures that no contaminated liquid can be re-introduced into the container after the drop has been dispensed. The patented PureFlow technology which is a separate venting system with a silicone membrane guarantees the intake of air which is free of contamination into the dispenser, after drop delivery.